Dianthus Therapeutics | MGTA - Assets



Dianthus Therapeutics reported $326.08M in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Adcock Ingram Holdings ZAR 8.74B 388.13M Dec/2024
Alaunos Therapeutics USD 2.76M 795K Dec/2024
Avita Medical AUD 79.71M 8.12M Dec/2024
Celltrion KRW 20.96T 96.41B Mar/2025
Cspc Pharmaceutical CNY 44.39B 3.51B Dec/2024
Dianthus Therapeutics USD 326.08M 47.93M Jun/2025
Divis Laboratories Ltd 169.32B 13.46B Mar/2025
IQVIA Holdings USD 28.63B 1.31B Jun/2025
Kangmei Pharma CNY 13.64B 69.1M Jun/2025
Knight Therapeutics CAD 962.29M 16.93M Sep/2024
Laboratorios Farma EUR 869.6M 37.58M Jun/2025
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 65.33M 6.17M Dec/2024
Moderna USD 12.01B 694M Jun/2025
Neuren Pharmaceuticals AUD 409.71M 181.55M Dec/2024
Organigram Holdings CAD 564.62M 85.41M Jun/2025
Organon & Co USD 13.5B 344M Jun/2025
Pharma Mar EUR 348.25M 14.75M Jun/2025
Qiagen NV USD 5.82B 278.39M Jun/2025
Revvity USD 12.36B 2.06M Jun/2025
Sartorius EUR 10.03B 85.1M Jun/2025
Sino Biopharmaceutical CNY 65.41B 1.3B Dec/2024
Tectonic Therapeutic USD 295.31M 142.4M Jun/2025
Tilray USD 4.19B 70.11M Nov/2024
Viatris USD 38.41B 63.4M Jun/2025
Xeris Pharmaceuticals USD 334.69M 11.63M Jun/2025
Zz Pientze Pharmaceu 18.71B 224.21M Jun/2025